The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Genetic variants associated with toxicity-related discontinuation of adjuvant aromatase inhibitor (AI) therapy.
Norah Lynn Henry
Research Funding - AstraZeneca; Lilly
Todd C. Skaar
No relevant relationships to disclose
Jessica Dantzer
No relevant relationships to disclose
Lang Li
No relevant relationships to disclose
Anne T Nguyen
No relevant relationships to disclose
James M. Rae
No relevant relationships to disclose
Zeruesenay Desta
No relevant relationships to disclose
Steffi Oesterreich
No relevant relationships to disclose
Santosh Philips
No relevant relationships to disclose
Janet S Carpenter
Consultant or Advisory Role - Lilly
Anna Maria Storniolo
Honoraria - Pfizer
Research Funding - Novartis; Pfizer
Vered Stearns
Honoraria - AstraZeneca
Research Funding - Novartis; Pfizer
Daniel F. Hayes
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - AstraZeneca; Novartis; Pfizer
David A. Flockhart
Research Funding - AstraZeneca; Novartis; Pfizer